We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Call on FDA to Clarify Biosimilar Statistical Approaches Guidance
Drugmakers Call on FDA to Clarify Biosimilar Statistical Approaches Guidance
Genentech and Pfizer urged the FDA in written comments to make its draft guidance on statistical analyses of analytical similarity data for biosimilars more specific and narrower in scope.